CN113150084B - Nanocrystallized coronavirus antigen and application thereof - Google Patents

Abstract

The invention discloses a nano coronavirus antigen and application thereof. The nano coronavirus antigen is obtained by polysaccharide covalent coupling 2019-nCoV RBD protein; the 2019-nCoV RBD protein comprises: amino acids 319 to 541 of S protein with GenBank accession number of MN908947.3 or a variant of the amino acid sequence; the variants have at least 70% sequence homology to the pre-mutation sequence and retain at least the antigenicity of the pre-mutation sequence. The nano coupled RBD antigen overcomes the defect of insufficient immunogenicity of RBD monomers, and greatly improves the titer of a neutralizing antibody of a mouse against 2019-nCoV.

Description

Nanocrystallized coronavirus antigen and application thereof

Technical Field

The invention belongs to the field of biomedicine, and particularly relates to a nano coronavirus antigen and application thereof, in particular to a novel nano coronavirus vaccine based on a polymer-coupled receptor binding region and application thereof.

Background

The novel coronavirus belongs to the genus coronavirus of the family Coronaviridae, is a positive-strand RNA virus with an envelope, and the genome of the positive-strand RNA virus is largest among all RNA viruses, and animals and humans are hosts of the coronavirus. Among them are 7 kinds of coronavirus infecting human, including severe respiratory syndrome coronavirus (SARS-CoV) outbreak in china in 2002-2003, middle east respiratory syndrome coronavirus (MERS-CoV) outbreak in 2012 and continuing to date, and novel coronavirus (2019-nCoV) outbreak in 2019, which are the biggest public health threats to the world. The new coronavirus was formally named by the world health organization at 12.1.2020. It is a new strain of coronavirus that has not been previously found in humans, the seventh coronavirus that can infect humans. The incubation period of human infection 2019-nCoV is generally 1-14 days, and after infection, common signs comprise respiratory symptoms, fever, cough, shortness of breath, dyspnea and the like. In more severe cases, the infection can lead to pneumonia, severe acute respiratory syndrome, renal failure, and even death. By 30 days 12 months in 2020, more than 8 million global cumulative corroboration cases and more than 170 million deaths can be confirmed. Therefore, the development of a safe and effective vaccine against the novel coronavirus (2019-nCoV) is very urgent and has important significance.

The surface spike protein (S protein) is the major neutralizing antigen of the novel coronavirus. 2019-nCoV invades cells by binding to the host cell's Receptor angiotensin converting enzyme 2 (ACE 2) through the Receptor Binding Domain (RBD) region. Thus, the Receptor Binding Domain (RBD) of the S protein of the novel coronavirus is considered to be the most important antigen-targeting domain that induces the body to produce neutralizing antibodies. The RBD protein as a vaccine antigen can focus the neutralizing antibody generated by the stimulation of an organism on the combination of a receptor aiming at the virus, and can improve the immunogenicity and the immune efficiency of the vaccine.

The target antigens for novel coronavirus vaccines are generally in the form of full-length S protein and truncated S protein (S1 and RBD). The types under investigation for novel coronavirus vaccines include adenoviral vector vaccines, mRNA vaccines, DNA vaccines, recombinant protein vaccines and inactivated vaccines. The invention aims to provide a novel coronavirus vaccine which is in a novel vaccine form and has enhanced immunogenicity and is based on the nanocrystallization of a receptor binding region coupled by a polymer.

In addition, previous studies of coronavirus vaccines have used RBD monomers, which have some neutralizing immunogenicity. However, current vaccines developed based on novel coronavirus S protein RBD monomers have limited immunogenicity. The RBD-based fusion protein (such as Fc fragment of IgG) has the defect of insufficient safety evaluation. Therefore, the development of a novel coronavirus vaccine with high immunogenicity and better safety is a problem to be solved.

Disclosure of Invention

The invention aims to solve the technical problem of providing a nano coronavirus antigen and application thereof in order to overcome the defect of limited immunogenicity of a coronavirus vaccine in the prior art. Compared with the RBD protein antigen, the coronavirus antigen can obviously improve the level of a host neutralizing antibody, has simple preparation method, no purification label and easy purification of the protein, has no biosafety risk, and can be applied to clinical application at high speed and low cost.

The invention mainly solves the technical problems through the following technical scheme.

One of the technical schemes of the invention is as follows: a nano-sized coronavirus antigen obtained by covalently coupling a polysaccharide to a 2019-nCoV RBD protein; the 2019-nCoV RBD protein comprises:

amino acids 319 to 541 of S protein with GenBank accession number of MN908947.3 or a variant of the amino acid sequence; the variants have at least 70% sequence homology to the pre-mutation sequence and retain at least the antigenicity of the pre-mutation sequence.

For example, the 2019-nCoV RBD protein comprises or is amino acids 319 to 587 of the S protein with GenBank accession number MN 908947.3.

The mutation sites encompassed by the variants may be conventional in the art, for example: starr et al, 2020, cell 182, 1295-1310 or bioRxiv preprint doi https:// doi. Org/10.1101/2020.03.15.991844. Preferably, the point mutations are one or more of C538S, C538A, S477N, N439K, N501Y, N354D, D364Y, V367F, W436R, I358F, Y365W, and F392W.

In a preferred embodiment of the invention, the amino acid sequence of the 2019-nCoV RBD protein comprises a sequence shown as any one of SEQ ID NO 1-3; preferably, the nucleotide sequence encoding the 2019-nCoV RBD protein comprises a nucleotide sequence shown as SEQ ID NO. 4, SEQ ID NO. 5 or SEQ ID NO. 6.

As for the polysaccharide in the present invention, it may be a microbial natural polysaccharide, a plant natural polysaccharide or an animal natural polysaccharide.

Wherein the microbial natural polysaccharide preferably comprises a bacterial capsular polysaccharide, an O-specific polysaccharide of a bacterial lipopolysaccharide, a bacterial exopolysaccharide and a fungal polysaccharide; the bacterial capsular polysaccharide is preferably a streptococcus pneumoniae polysaccharide, more preferably a streptococcus pneumoniae polysaccharide type 9V;

the plant natural polysaccharide preferably comprises amylose, inulin, cellulose and pectin;

the animal natural polysaccharides preferably include chitin, glycogen, hyaluronic acid and heparin.

The covalent coupling in the present invention can be achieved by conventional means in the art, and preferably the chemical principle of the covalent coupling is reductive amination, carbodiimide-mediated condensation, thioalkylation, active ester or cyanation.

Among them, the coupling reagent used for carrying out the cyanation reaction is preferably 1-cyano-4- (dimethylamino) pyridyltetrafluoroborate. The coupling reagent used to perform the cyanation reaction preferably activates the hydroxyl groups on the polysaccharide, while coupling lysine residues on the 2019-nCoV RBD protein to form a coupled product.

In a preferred embodiment of the present invention, the method for preparing coronavirus antigen comprises: and mixing the polysaccharide activated by the coupling reagent with 2019-nCoV RBD protein, and reacting. The mass ratio of the polysaccharide activated by the coupling reagent to the 2019-nCoV RBD protein is preferably (0.2-2): 1, and more preferably 1.

Preferably, after the reaction is finished, the reaction product is purified by dialysis or ultrafiltration through 0.9% sodium chloride solution.

The second technical scheme of the invention is as follows: a medicament comprising a coronavirus antigen according to any one of the preceding claims. The medicament preferably further comprises an aluminum adjuvant.

The third technical scheme of the invention is as follows: the application of the coronavirus antigen in the technical scheme in the preparation of vaccine medicines for preventing novel coronavirus. The vaccine medicament preferably further comprises an aluminium adjuvant.

The fourth technical scheme of the invention is as follows: a method of increasing the immunogenicity of a coronavirus antigen, the method comprising covalently coupling a 2019-nCoV RBD protein with a polysaccharide to form a nanoized vaccine antigen.

The fourth technical scheme is that 2019-nCoV RBD protein, polysaccharide, covalent coupling and the like are further defined in one of the technical schemes.

The fifth technical scheme of the invention is as follows: a method of making a nano-sized coronavirus antigen, the method comprising: mixing and reacting the polysaccharide activated by the coupling reagent with 2019-nCoV RBD protein;

the 2019-nCoV RBD protein comprises:

amino acids 319 to 541 of S protein with GenBank accession number of MN908947.3 or a variant of the amino acid sequence;

the variants have at least 70% sequence homology to the pre-mutation sequence and retain at least the antigenicity of the pre-mutation sequence.

The method preferably further comprises the step of purifying the reaction product by dialysis or ultrafiltration with a 0.9% sodium chloride solution.

The 2019-nCoV RBD protein can be directly synthesized by a biological company or obtained by expression and purification of engineering bacteria. In one embodiment of the invention, the 2019-nCoV RBD protein purification method comprises the steps of filtering cell supernatant expressing the antigen to remove cell debris, or removing impurities and polymers in a flow-through mode through a cation exchange column after bacterial inclusion bodies are renatured, carrying out coarse purification on target protein, then passing the target protein-containing component through a pH-adjusted cation exchange column, carrying out salt gradient elution, combining obtained elution peaks containing the target protein, carrying out retention concentration through a 10kDa MWCO membrane, transferring the sample into a buffer solution for storing the sample, or further purifying and concentrating through a hydrophobic chromatography column.

1) The bacterial inclusion bodies were washed, dissolved in a high concentration denaturant (8M urea or 6M guanidine hydrochloride) at a pH of 7.0 to 10.0 at room temperature, and then added to a renaturation solution at a concentration of 0.1 to 1 mg/ml. The denaturating solution contains 2-5M urea, oxidation-reduction agent (glutathione, cysteine/cystine, cysteamine/cystamine), oxidant concentration is 0.05-0.5mM, reducing agent concentration is 0.05-2mM, and renaturation is carried out for 16-60 hours at 4-10 ℃.

2) Cation columns used in the course of rough purification include SP Sepharose Big beads of Cytiva, SP Sepharose Fast Flow, toyopearl SP-550C of Toyopearl SP-650M of Tokyo, SP Bestarose FF of Booglon, and the like.

3) Cation columns used in the fine purification include SP Sepharose HP, source30S, from Cytiva, eshmuon CPS, from Merck, toyopearl Sulfate-650F, from Tokyo, SP Bestarose HP, from Booglon, and the like.

4) The filler used for hydrophobic purification includes Phenyl Sepharose Fast Flow (high Sub) of Cytiva, phenyl Sepharose Fast Flow (Low Sub), butyl Sepharose Fast Flow, phenyl Bestarose FF (HS) of Bordeten, butyl Bestarose 4FF and the like.

On the basis of the common knowledge in the field, the above preferred conditions can be combined randomly to obtain the preferred embodiments of the invention.

The reagents and starting materials used in the present invention are commercially available.

The positive progress effects of the invention are as follows:

the invention forms the nano vaccine antigen by recombining RBD protein antigen and polymers such as microbial polysaccharide through chemical coupling. And respectively immunizing Balb/c mice by using purified RBD protein monomers and nano-coupled RBD antigens. The nano coupled RBD antigen overcomes the defect of insufficient immunogenicity of RBD monomers, greatly improves the generation of the titer of a neutralizing antibody of a mouse against 2019-nCoV, and has strong positive inhibition rate results under 20-fold dilution of serum.

Drawings

FIG. 1 is a SDS-PAGE pattern of E.coli expressed RBD antigen; m is protein marker, S is cell lysis supernatant, P is cell lysate sediment, R is Reduced SDS-PAGE, and NR is Non-Reduced SDS-PAGE.

FIG. 2 is a SDS-PAGE picture of RBD antigen expression in HEK293 cells.

FIG. 3 is a graph of the mass-spectrometric accurate molecular weight of an E.coli expressed RBD antigen.

Detailed Description

The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.

The vector used for the plasmid of the target gene is pETK, which is purchased from Suzhou Jinzhi Biotechnology GmbH.

BL21 (DE 3) competent cells were purchased from Beijing Quanjin Biotechnology, inc.

The formula of the liquid LB culture medium is 10g/L tryptone, 5g/L yeast extract, 10g/L sodium chloride and pH7.0.

Example 1: preparation of the escherichia coli engineering bacteria for expressing the 2019-nCoV recombinant RBD antigen entrusts Suzhou Jinwei to synthesize a plasmid for expressing a target protein, and sequencing verification is correct.

BL21 (DE 3) competent cells were transformed with the correct plasmid containing the desired gene (sequences shown in SEQ ID NOS: 4, 5 and 6, respectively), and the cells were monoclonally inoculated into 3mL of liquid LB medium containing 100ng/mL of kanamycin, and cultured overnight at 220rpm and 30 ℃ with shaking, to give seeds.

The seeds were inoculated into TB medium containing 100ng/mL kanamycin at 1.

The 10OD cells were resuspended in 1ml lysis buffer (10 mM Tris-HCl, pH 8.0), disrupted by sonication, assayed for total protein by SOP, and the supernatant and pellet fractions were analyzed by SDS-PAGE, the results of which are shown in FIG. 1.

Example 2: preparation of Expi293 recombinant cells expressing 2019-nCoV recombinant RBD antigen A plasmid of the correctly sequenced target gene was extracted with QIAGEN plasmid extraction kit for use.

Expi293 cell suspensions freshly passaged to 2.0-2.5 × 10E 6/mL were prepared according to the volume required for transfection.

Transfection reagent-plasmid complexes were prepared, namely, solution A (plasmid/Opti-MEM (1. Mu.g/50. Mu.L)) and solution B (PEI/Opti-MEM (5. Mu.L/50. Mu.L)), which were incubated for 10 minutes independently.

Adding B dropwise to solution A, incubating at room temperature for 10min, adding dropwise cell suspension, shake culturing (115rpm, 36.8 deg.C, 5% CO) ₂ ) After 24 hours, 0.4mL of KTfeed can be added, the shaking culture is continued for 5 to 7 days under the same conditions, and the cell supernatant is collected by centrifugation at 8500rpm for 15min and then submitted to downstream purification.

SDS-PAGE analysis of the supernatant according to SOP was carried out, and the analysis results are shown in FIG. 2.

Example 3: purification and identification of 2019-nCoV recombinant RBD antigen escherichia coli or cell expression

The E.coli-expressing cells of example 1 were resuspended at 1. Inclusion bodies were denatured by dissolution in 20mM ethylene glycol, 8M Urea,50mM DTT pH8.0, and then renatured with 20mM Tris, pH8.0,3M urea, 0.05mM cysteamine, 1mM cysteamine renaturation solution for 20 hours. Adjusting the pH value of the renaturation supernatant fluid to 7, centrifuging for 1 hour at 10000 Xg, taking the supernatant fluid, purifying by Cytiva SP Sepharose Fast Flow in a Flow-through mode to remove HCP (Host cell protein) and polymer, and carrying out coarse purification on the target protein; adjusting the pH value of the flow-through solution to 5, performing further fine purification by using Cytiva SP sepharose HP in a binding mode, performing gradient elution on target protein by using 1M NaCl, combining elution peaks containing the target protein, performing dense concentration by using 10kDa MWCO, and changing the solution into 2 XPBS buffer solution for further polysaccharide coupling. The molecular weight identification map is shown in FIG. 3, and the complete molecular weight is determined according to liquid phase mass spectrometry: 30285.7Da in agreement with the theoretical molecular weight (30284.79 Da).

The cell supernatants expressing the antigens of example 2 were filtered to remove cell debris. Adjusting the pH of cell supernatant to 7.0, removing HCP and polymers in a Flow-through mode through a Cytiva SP Fast Flow cation exchange column to carry out coarse purification on target protein, adjusting the pH of Flow-through liquid to 4.0, then further carrying out fine purification on the SP sepharose HP loaded on the cation exchange column, carrying out gradient elution by using 1M NaCl, combining elution peaks containing the target protein, carrying out concentration by using a 10kDa MWCO dense-pulse concentration tube, and exchanging the liquid into 2 x PBS buffer solution for further polysaccharide coupling.

Example 4: fermentation, purification and identification of bacterial hyaluronic acid polysaccharide

Culturing the streptococcus zooepidemicus bacterial strain expressing hyaluronic acid polysaccharide at 37 ℃ for 10 hours by a tryptone culture medium to obtain a supernatant or thallus containing the corresponding bacterial polysaccharide. The bacterial culture solution is inactivated by 0.5 percent of formaldehyde, and then centrifuged at 8000g for 30 minutes to collect supernatant. Ultrafiltering and concentrating the centrifugal supernatant by a 100kDa membrane package, performing fractional precipitation by adopting 25-80% ethanol, and collecting the precipitate to obtain crude polysaccharide; dissolving polysaccharide in sterilized water for injection, ultrafiltering, dialyzing, refining with ion exchange filler by series chromatography or fractional chromatography, collecting flow-through peak, desalting by ultrafiltration dialysis, lyophilizing to obtain refined hyaluronic acid polysaccharide, and storing at-20 deg.C.

Measuring the content of residual protein (required to be less than or equal to 1%) in the refined hyaluronic acid polysaccharide by adopting a Lowry method; measuring the content of residual nucleic acid (required to be less than or equal to 1%) by adopting an ultraviolet spectrophotometry; measuring the content of uronic acid (required to be more than or equal to 44%) by a sulfuric acid-carbazole method; the weight average molecular weight is determined by HPLC-SEC-MALLS method (requirement is more than or equal to 10) ⁵ Da)。

Table 1: quality attributes of refined hyaluronic acid polysaccharides

Example 5: fermentation, purification and identification of pneumococcal capsular polysaccharide

The bacterial strain of streptococcus pneumoniae expressing 9V type capsular polysaccharide is cultured for 10 hours at 37 ℃ by a tryptone medium to obtain thalli containing the corresponding bacterial polysaccharide. The bacterial culture solution is inactivated by 0.5% sodium deoxycholate, centrifuged at 8000g for 30 minutes, and the supernatant is collected. Ultrafiltering and concentrating the centrifugal supernatant by a 100kDa membrane package, performing fractional precipitation by adopting 25-80% ethanol, and collecting the precipitate to obtain crude polysaccharide; dissolving polysaccharide with sterilized water for injection, ultrafiltering, dialyzing, refining with ion exchange filler by series chromatography or fractional chromatography, collecting flow-through peak, desalting by ultrafiltration dialysis, lyophilizing to obtain refined 9V pneumococcal polysaccharide, and storing at-20 deg.C.

Measuring residual protein content (required to be less than or equal to 1%) by Lowry method for refined 9V pneumococcal polysaccharide; measuring the content of residual nucleic acid (required to be less than or equal to 1%) by using an ultraviolet spectrophotometry; measuring the content of uronic acid (required to be more than or equal to 15%) by a sulfuric acid-carbazole method; hexosamine content (required to be more than or equal to 13%); the weight average molecular weight is determined by HPLC-SEC-MALLS method (requirement is more than or equal to 10) ⁵ g.mol ^-1 )。

Table 2: quality attribute of refined 9V type pneumococcal polysaccharide

Example 6: covalent coupling of microbial polysaccharides of 2019-nCoV recombinant RBD antigens

The recombinant RBD antigen obtained in example 3 is activated by coupling reagent 1-cyano-4- (dimethylamino) pyridine tetrafluoroborate (CDAP) to ferment a polysaccharide product, namely hyaluronic acid polysaccharide (HA), then RBD protein and the activated polysaccharide are mixed and reacted according to the feeding mass ratio of 1. And (4) determining the RBD protein content in the purified antigen by adopting a Lowry method.

Example 7: immunization experiment of mice

The conjugated antigen obtained in example 6 was diluted in physiological saline according to the method shown in Table 3 and formulated with an aluminum adjuvant. Then 4-6 weeks old Balb/C female mice were immunized in groups. The immunization procedure is as in table 3, i.e. by means of inguinal subcutaneous injection, each mouse received 2 vaccine immunizations each at day 0, day 14, in a vaccination volume of 100 μ l each time. On day 28 (i.e., day 14 after the 2-pin immunization), the mice were subjected to orbital bleeds. The mouse serum is obtained by centrifugation at 3000rpm for 10 minutes after the serum is separated out after standing for a period of time, and is stored at-20 ℃ and below for detection of neutralizing antibody titer and pseudovirus neutralizing titer.

Table 3: animal immunization group status

Example 8: serum IgG Total antibody Titer assay

The test adopts an indirect ELISA method to detect the IgG total antibody titer aiming at the new coronavirus RBD in the serum of mice of each test group.

i) Antigen coating

Respectively adopting S1 protein and RBD protein as coating antigens, coating an ELISA plate with protein concentration of 10 mug/ml and 100 mul per hole, and coating overnight at 4 ℃.

ii) serum dilution and incubation

The test group sera (10-fold initial) were diluted 2-fold, 100. Mu.l per well, added to the microplate, and incubated for 120 min at 37 ℃.

iii) Plate washer alkaline phosphatase IgG secondary antibody incubation

Add 200 mul of washing liquid into each hole to wash the enzyme label plate for 5 times. Then, a 4000-fold dilution of goat anti-mouse IgG alkaline phosphatase secondary antibody was added and incubated at 37 ℃ for 120 minutes.

iv) plate washing and color development

Adding 200 mul of cleaning solution into each hole to clean the enzyme label plate, and cleaning for 5 times; after the plate is washed, 100 microliter of color development liquid is added into each hole. After development at 20-25 ℃ for 60 minutes under dark conditions, 50. Mu.L of stop solution was added.

v) standards for reading and result determination

The plate is placed in a microplate reader, and the reading is 405 nm. When analyzing the result, the positive and negative Cutoff values are calculated, and the calculation formula is as follows. Based on the Cutoff value, the IgG antibody titer of the sample was calculated.

Cutoff value = OD405 mean +2SD of sample wells of negative group

vi) analysis of test results

In the test groups (test groups 5 and 6) of prokaryotic and eukaryotic expression RBD monomeric proteins, after 2-needle immunization at a dose of 10 mu g, the generation of IgG antibody level with high titer aiming at the 2019-nCoVRBD region can be induced in a mouse body; RBD protein test groups (test groups 1, 2) covalently coupled with bacterial polysaccharides induced high titers of IgG antibody production against the 2019-nCoVRBD region in mice after immunization for 2 needles at a dose of 10 μ g. And the RBD protein test groups (test groups 3 and 4) after covalent coupling of bacterial polysaccharides can also generate higher neutralizing antibody levels after 2-needle immunization at a low dose of 1 mu g and are comparable to the test group 1. The results are detailed in Table 4.

The results show that the RBD monomeric protein has certain immunogenicity and can generate higher total IgG antibody level by coupling with bacterial polysaccharide. This suggests the immunological feasibility of bacterial polysaccharide-conjugated RBD antigens as vaccines, and further confirmation of whether the produced IgG antibodies have neutralizing protective activity is required.

TABLE 4 detection of neutralizing antibody levels in antigen-challenged mice (20-fold dilution)

Example 9: serum neutralizing antibody titer determination assay

The test was carried out using a commercially available cPass from Kinry corporation ^TM The sVNT Kit detects the titer of the neutralizing antibody of the new coronavirus in the serum of mice of each test group. cPass ^TM This technique allows rapid detection of total neutralizing antibodies (NAbs) in a sample by mimicking the process of interaction between the virus and host cells. In order for a virus to infect a host cell, the viral receptor binding protein (RBD) first needs to interact with the membrane receptor protein (ACE 2) of the host cell. The interaction of the virus with the host cell and subsequent infection with the virus results in the activation of an immune response in the individual, thereby generating a population of antibodies against the virus. Some of these antibodies bind to the virus but do not necessarily prevent viral infection. Other antibodies may bind to RBD in a manner that blocks interaction with ACE2 receptors. This result helps to distinguish whether the sample contains NAbs that may specifically block the interaction and thus the entry of the virus into the host cell.

i) Serum dilution and incubation

The positive control serum, the negative control serum and the test group serum (20-fold initial) were diluted 2-fold, mixed with the HRP-labeled RBD protein at a volume of 1.

ii) incubation of Mixed-solution ELISA plates

And (3) sucking 100 mu L of mixed liquid of the positive quality control serum, the negative quality control serum and the test group serum, adding the mixed liquid into an ELISA plate hole, and incubating for 15 minutes at 37 ℃.

iii) Plate washing and color development

Adding 260 mu L of cleaning solution into each hole, and washing the plate for 4 times; after the plate is washed, 100 mu L of TMB color developing solution is added into each hole. After development at 20-25 ℃ for 15 minutes under dark conditions, 50. Mu.L of stop solution was added.

iiii) reading and result criteria

And (4) placing the enzyme label plate into an enzyme label instrument, and reading at 450 nm. In the analysis of the results, it is necessary to determine whether the results of the system's negative and positive sera are true, and the determination criteria are shown in Table 5.

TABLE 5 systematic negative and positive determination criteria

Quality control project	OD 450nm	Quality control qualification requirement
			Negative quality control	＞1.0	Negative quality control establishment
Positive quality control	＜0.3	Positive quality control establishment

The titer of the serum neutralizing antibody of the test group is calculated by inhibiting the ACE2 binding rate, and the calculation formula is as follows:

inhibition rate = (1-test group sample OD value/negative quality control group OD value) × 100%

The Cutoff value criteria for the negative and positive inhibition of neutralizing antibody titers in the sample groups are shown in Table 6:

TABLE 6 2019-nCoV neutralization antibody titer negative-positive inhibition ratio Cutoff value standard

iiii) analysis of test results

In prokaryotic and eukaryotic expression RBD monomeric protein test groups (test groups 5 and 6), after 2 needles of immunization with 10 mu g of dose, neutralizing antibody level aiming at 2019-nCoV is generated at the inducible part in a mouse body, but the neutralizing antibody level is lower; the RBD protein test groups (test groups 1 and 2) after covalent coupling of bacterial polysaccharide can induce the generation of neutralizing antibody level against 2019-nCoV in mice after 2 times of immunization at the dose of 10 mu g, and the antibody level is higher. And the RBD protein test groups (test groups 3 and 4) after the covalent coupling of the bacterial polysaccharide can also generate higher neutralizing antibody level after 2 times of immunization at the low dose of 1 mu g and are comparable to the test groups 1 and 2. The results are detailed in Table 7.

TABLE 7 detection of neutralizing antibody levels in test antigen-primed mice

The results show that the RBD monomeric protein has certain immunogenicity, and weak neutralizing antibody levels are generated after immunization. After coupling of various bacterial polysaccharides, the immunogenicity of the RBD protein is obviously enhanced, and a higher level of neutralizing antibodies can be generated at a lower dose. This suggests that the immunogenicity of the 2019-nCoV vaccine can be significantly improved when the bacterial polysaccharide-coupled RBD antigen is used as a vaccine, and the protective neutralizing antibody level has obvious advantages.

SEQUENCE LISTING

<110> Jiangsu Kunli biopharmaceutical Limited liability company;

BEIJING ZHIDAO BIOLOGICAL TECHNOLOGY Co.,Ltd.

<120> nano coronavirus antigen and application thereof

<130> P21011424C

<140> CN 2021103097070

<141> 2021-03-23

<160> 6

<170> PatentIn version 3.5

<210> 1

<211> 223

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> 2019-nCoV RBD protein amino acid sequence

<400> 1

Arg Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn

1 5 10 15

Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val

20 25 30

Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser

35 40 45

Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val

50 55 60

Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp

65 70 75 80

Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln

85 90 95

Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr

100 105 110

Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly

115 120 125

Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys

130 135 140

Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr

145 150 155 160

Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser

165 170 175

Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val

180 185 190

Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly

195 200 205

Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe

210 215 220

<210> 2

<211> 270

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> amino acid sequence of 2019-nCoV RBD protein

<400> 2

Met Arg Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr

1 5 10 15

Asn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser

20 25 30

Val Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr

35 40 45

Ser Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly

50 55 60

Val Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala

65 70 75 80

Asp Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly

85 90 95

Gln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe

100 105 110

Thr Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val

115 120 125

Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu

130 135 140

Lys Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser

145 150 155 160

Thr Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln

165 170 175

Ser Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg

180 185 190

Val Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys

195 200 205

Gly Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Ser Val Asn Phe

210 215 220

Asn Phe Asn Gly Leu Thr Gly Thr Gly Val Leu Thr Glu Ser Asn Lys

225 230 235 240

Lys Phe Leu Pro Phe Gln Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr

245 250 255

Asp Ala Val Arg Asp Pro Gln Thr Leu Glu Ile Leu Asp Ile

260 265 270

<210> 3

<211> 270

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> amino acid sequence of 2019-nCoV RBD protein

<400> 3

Met Arg Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr

1 5 10 15

Asn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser

20 25 30

Val Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr

35 40 45

Ser Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly

50 55 60

Val Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala

65 70 75 80

Asp Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly

85 90 95

Gln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe

100 105 110

Thr Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val

115 120 125

Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu

130 135 140

Lys Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser

145 150 155 160

Thr Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln

165 170 175

Ser Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg

180 185 190

Val Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys

195 200 205

Gly Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe

210 215 220

Asn Phe Asn Gly Leu Thr Gly Thr Gly Val Leu Thr Glu Ser Asn Lys

225 230 235 240

Lys Phe Leu Pro Phe Gln Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr

245 250 255

Asp Ala Val Arg Asp Pro Gln Thr Leu Glu Ile Leu Asp Ile

260 265 270

<210> 4

<211> 813

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> 2019-nCoV RBD protein nucleotide sequence

<400> 4

atgcgcgttc agcctacaga atcaattgtt cgctttccta acattacaaa cctttgtcct 60

ttcggagagg tcttcaatgc aacacgcttt gcttcagttt atgcttggaa ccgcaaacgc 120

atttcaaact gtgttgctga ttattcagtt ctttataact cagcttcatt ctccacgttt 180

aaatgttatg gcgtttcacc tacaaagctg aatgatcttt gtttcactaa tgtttatgct 240

gattcatttg ttattcgcgg cgatgaagtt cgccagattg ctcctggcca gacaggcaag 300

atagcggatt ataactataa acttcctgat gatttcaccg gatgtgttat tgcttggaac 360

tcaaacaacc tcgattcaaa ggtgggtggc aactataact atctttatcg cctattcaga 420

aagtcaaacc ttaaaccttt cgagcgggat atttcaacag aaatttatca ggctggctca 480

acaccttgta acggcgttga aggctttaac tgttatttcc cgttacagtc ttatggcttt 540

cagcctacaa acggcgttgg ctatcagcct tatcgcgttg ttgttctttc atttgaactt 600

cttcatgctc ctgctacagt ttgtggccct aagaagagca ctaaccttgt taagaataag 660

tgtgttaact ttaactttaa cggccttaca ggcacaggcg ttcttacaga atcaaacaag 720

aagtttctgc catttcagca gtttggccgc gatattgctg atacaaccga cgccgtcaga 780

gaccctcaga cacttgaaat tcttgatatt taa 813

<210> 5

<211> 813

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> 2019-nCoV RBD protein nucleotide sequence

<400> 5

atgcgcgttc agcctacaga atcaattgtt cgctttccta acattacaaa cctttgtcct 60

ttcggagagg tcttcaatgc aacacgcttt gcttcagttt atgcttggaa ccgcaaacgc 120

atttcaaact gtgttgctga ttattcagtt ctttataact cagcttcatt ctccacgttt 180

aaatgttatg gcgtttcacc tacaaagctg aatgatcttt gtttcactaa tgtttatgct 240

gattcatttg ttattcgcgg cgatgaagtt cgccagattg ctcctggcca gacaggcaag 300

atagcggatt ataactataa acttcctgat gatttcaccg gatgtgttat tgcttggaac 360

tcaaacaacc tcgattcaaa ggtgggtggc aactataact atctttatcg cctattcaga 420

aagtcaaacc ttaaaccttt cgagcgggat atttcaacag aaatttatca ggctggctca 480

acaccttgta acggcgttga aggctttaac tgttatttcc cgttacagtc ttatggcttt 540

cagcctacaa acggcgttgg ctatcagcct tatcgcgttg ttgttctttc atttgaactt 600

cttcatgctc ctgctacagt ttgtggccct aagaagagca ctaaccttgt taagaataag 660

tctgttaact ttaactttaa cggccttaca ggcacaggcg ttcttacaga atcaaacaag 720

aagtttctgc catttcagca gtttggccgc gatattgctg atacaaccga cgccgtcaga 780

gaccctcaga cacttgaaat tcttgatatt taa 813

<210> 6

<211> 672

<212> DNA

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> 2019-nCoV RBD protein nucleotide sequence

<400> 6

agagtgcaac ctacagaatc aatcgtgaga tttcctaaca tcacaaacct ttgccctttc 60

ggagaagtgt tcaatgctac aagatttgca tcagtgtacg catggaacag aaagaggata 120

tcaaactgcg tggcagatta ctcagtgctt tacaactcag catcattctc tacctttaaa 180

tgctacggag tgtcacctac aaagttaaat gatctttgct ttacaaacgt gtacgcagat 240

tcatttgtga tcagaggaga tgaagtgaga caaatcgcac ctggacaaac aggaaagata 300

gctgattaca actacaaact tcctgatgat ttcaccgggt gcgtgatcgc atggaactca 360

aacaacttgg attcaaaggt gggaggcaat tataattatt tatatcgttt atttaggaag 420

tccaacctca aacctttcga gcgagatatc tcaacagaaa tctaccaagc aggatcaaca 480

ccttgcaacg gagtggaagg atttaactgc tactttcctc ttcaatcata cggatttcaa 540

cctacaaacg gagtgggata ccaaccttac agagtggtgg tgctttcatt tgaacttctt 600

cacgcacctg caacagtgtg cggacctaag aagagtacga accttgtgaa gaataagtgc 660

gtgaactttt ag 672

Claims (16)

1. A nano coronavirus antigen is characterized by being obtained by covalently coupling polysaccharide to 2019-nCoV RBD protein, wherein the amino acid sequence of the 2019-nCoV RBD protein is a sequence shown in any one of SEQ ID NO: 1-3, and the polysaccharide is: streptococcus pneumoniae polysaccharides, hyaluronic acid.

2. The coronavirus antigen of claim 1, wherein the nucleotide sequence encoding the 2019-nCoV RBD protein is the nucleotide sequence shown in SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 6.

3. The coronavirus antigen of claim 1, wherein said streptococcus pneumoniae polysaccharide is a streptococcus pneumoniae polysaccharide type 9V.

4. The coronavirus antigen of claim 1, wherein the covalent coupling is based on the chemical principle of reductive amination, carbodiimide-mediated condensation, thioalkylation, active ester or cyanation.

5. The coronavirus antigen of claim 4, wherein the coupling reagent used in the cyanation reaction is 1-cyano-4- (dimethylamino) pyridyltetrafluoroborate;

and/or, performing the cyanation reaction by using a coupling reagent to activate hydroxyl on the polysaccharide and simultaneously coupling lysine residues on the 2019-nCoV RBD protein to form a coupling product.

6. The coronavirus antigen according to any one of claims 1 to 5, which is prepared by a method comprising: and mixing the polysaccharide activated by the coupling reagent with 2019-nCoV RBD protein, and reacting.

7. The coronavirus antigen of claim 6, wherein the coupling reagent-activated polysaccharide to 2019-nCoV RBD protein mass ratio is (0.2-2): 1.

8. The coronavirus antigen of claim 7, wherein the coupling reagent-activated polysaccharide to 2019-nCoV RBD protein mass ratio is 1.

9. The coronavirus antigen of claim 6, wherein after completion of the reaction, the reaction product is purified by dialysis or ultrafiltration with 0.9% sodium chloride solution.

10. Use of a coronavirus antigen as claimed in any one of claims 1 to 9 in the preparation of a medicament for the prevention of a novel coronavirus.

11. The use of claim 10, wherein the medicament further comprises an aluminum adjuvant.

12. A medicament comprising a coronavirus antigen as claimed in any one of claims 1 to 9.

13. The medicament of claim 12, further comprising an aluminum adjuvant.

14. A method of increasing the immunogenicity of a coronavirus antigen, the method comprising forming a nanoconjugated vaccine antigen by covalent coupling of a 2019-nCoV RBD protein as defined in the coronavirus antigen of claim 1 or 2 with a polysaccharide as defined in the coronavirus antigen of claim 1.

15. The method of claim 14, wherein the covalent coupling is achieved by a reductive amination reaction, a carbodiimide-mediated condensation reaction, a thioalkylation reaction, an active ester reaction, or a cyanation reaction.

16. The method of claim 15, wherein the coupling reagent used in the cyanation reaction is 1-cyano-4- (dimethylamino) pyridyltetrafluoroborate;

and/or, performing the cyanation reaction by using a coupling reagent to activate hydroxyl on the polysaccharide and simultaneously coupling lysine residues on the 2019-nCoV RBD protein to form a coupling product.

Images